SR/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
302.4 |
umol/g |
4.2 |
10.29 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102238 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
300.3 |
umol/g |
4.7 |
11.51 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102245 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
298.7 |
umol/g |
3.2 |
7.84 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102259 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.3 |
umol/g |
4.4 |
10.78 |
osmometry |
0.0 |
0 |
|
102240 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
300.6 |
umol/g |
2.8 |
6.86 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102258 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.6 |
umol/g |
3.8 |
9.31 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102239 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
299.6 |
umol/g |
4.5 |
11.02 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102237 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
298.6 |
umol/g |
3.8 |
9.31 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102257 |
2682 |
SR/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
300.9 |
umol/g |
3.7 |
9.06 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102260 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
299.4 |
umol/g |
3.8 |
9.31 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102263 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.8 |
umol/g |
3.8 |
9.31 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102246 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.4 |
umol/g |
4.2 |
10.29 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102261 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.6 |
umol/g |
3.9 |
9.55 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102247 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.8 |
umol/g |
3.6 |
8.82 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102262 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.2 |
umol/g |
3.2 |
7.84 |
osmometry |
0.0 |
0 |
p osmolality mosm/kg |
102264 |
2682 |
SS/Hsd |
plasma osmolality |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood molecular composition trait |
male |
91 days-119 days |
6 |
301.3 |
umol/g |
4.3 |
10.53 |
osmometry |
0.0 |
0 |
|
102248 |
2682 |